[go: up one dir, main page]

PE20081801A1 - SOLID FORMS OF A RAF KINASE INHIBITOR - Google Patents

SOLID FORMS OF A RAF KINASE INHIBITOR

Info

Publication number
PE20081801A1
PE20081801A1 PE2008000420A PE2008000420A PE20081801A1 PE 20081801 A1 PE20081801 A1 PE 20081801A1 PE 2008000420 A PE2008000420 A PE 2008000420A PE 2008000420 A PE2008000420 A PE 2008000420A PE 20081801 A1 PE20081801 A1 PE 20081801A1
Authority
PE
Peru
Prior art keywords
diffraction pattern
characteristic peaks
includes characteristic
ray powder
solid forms
Prior art date
Application number
PE2008000420A
Other languages
Spanish (es)
Inventor
Ahmad Hashash
Kangwen L Lin
Augustus O Okhamafe
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20081801A1 publication Critical patent/PE20081801A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A FORMAS SOLIDAS DEL COMPUESTO 1-METIL-5-(2-(5-(TRIFLUOROMETIL)-1H-IMIDAZOL-2-IL)-PIRIDIN-4-ILOXI)-N-(4-(TRIFLUOROMETIL)-FENIL)-1H-BENZO[d]IMIDAZOL-2-AMINA TALES COMO A) LA FORMA SOLIDA A QUE TIENE UN PATRON DE DIFRACCION EN POLVO DE RAYOS X QUE COMPRENDE PICOS CARACTERISTICOS EN GRADOS 2O DE 9.0, 17.0, 18.4 Y 25.3, ENTRE OTROS; B) LA FORMA SOLIDA B QUE TIENE UN PATRON DE DIFRACCION EN POLVO DE RAYOS X QUE COMPRENDE PICOS CARACTERISTICOS EN GRADOS 2O DE 8.7, 12.2, 13.6, 17.9 Y 24.5; C) LA FORMA SOLIDA C QUE TIENE UN PATRON DE DIFRACCION EN POLVO DE RAYOS X QUE COMPRENDE PICOS CARACTERISTICOS EN GRADOS 2O DE 6.7, 7.6, 9.2, 9.6 Y 15.3; D) LA FORMA SOLIDA D QUE TIENE UN PATRON DE DIFRACCION EN POLVO DE RAYOS X QUE COMPRENDE PICOS CARACTERISTICOS EN GRADOS 2O DE 6.5 Y 11.6; E) LA FORMA SOLIDA E QUE TIENE UN PATRON DE DIFRACCION EN POLVO DE RAYOS X QUE COMPRENDE PICOS CARACTERISTICOS EN GRADOS 2O DE 7.5 Y 10.6; ENTRE OTROS. SE REFIERE TAMBIEN A PROCESOS DE PREPARACION DE LAS FORMAS SOLIDAS Y A COMPOSICIONES FARMACEUTICAS QUE LAS COMPRENDEN. DICHO COMPUESTO ES INHIBIDOR DE CINASA Raf SIENDO UTIL EN EL TRATAMIENTO DE TUMORESREFERS TO SOLID FORMS OF THE COMPOUND 1-METHYL-5- (2- (5- (TRIFLUORomethyl) -1H-IMIDAZOL-2-IL) -PYRIDIN-4-ILOXI) -N- (4- (TRIFLUOROMETHYL) -PHENYL) -1H-BENZO [d] IMIDAZOL-2-AMINE SUCH AS A) THE SOLID FORM THAT HAS A DIFFRACTION PATTERN IN X-RAY POWDER THAT INCLUDES CHARACTERISTIC PEAKS IN 2ND DEGREES OF 9.0, 17.0, 18.4 AND 25.3, AMONG OTHERS; B) THE SOLID FORM B THAT HAS A DIFFRACTION PATTERN IN X-RAY POWDER THAT INCLUDES CHARACTERISTIC PEAKS IN GRADES 2 OF 8.7, 12.2, 13.6, 17.9 AND 24.5; C) THE SOLID FORM C THAT HAS A DIFFRACTION PATTERN IN X-RAY POWDER THAT INCLUDES CHARACTERISTIC PEAKS IN DEGREES 2 OF 6.7, 7.6, 9.2, 9.6 AND 15.3; D) THE SOLID SHAPE D THAT HAS A DIFFRACTION PATTERN IN X-RAY DUST THAT INCLUDES CHARACTERISTIC PEAKS IN GRADES 2O OF 6.5 AND 11.6; E) THE SOLID FORM E THAT HAS A DIFFRACTION PATTERN IN X-RAY POWDER THAT INCLUDES CHARACTERISTIC PEAKS IN GRADES 2O OF 7.5 AND 10.6; AMONG OTHERS. IT ALSO REFERS TO PROCESSES FOR THE PREPARATION OF SOLID FORMS AND TO PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM. SAID COMPOUND IS INHIBITOR OF RAF KINASE, BEING USEFUL IN THE TREATMENT OF TUMORS

PE2008000420A 2007-03-02 2008-02-29 SOLID FORMS OF A RAF KINASE INHIBITOR PE20081801A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90445507P 2007-03-02 2007-03-02

Publications (1)

Publication Number Publication Date
PE20081801A1 true PE20081801A1 (en) 2009-01-08

Family

ID=39456506

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000420A PE20081801A1 (en) 2007-03-02 2008-02-29 SOLID FORMS OF A RAF KINASE INHIBITOR

Country Status (25)

Country Link
US (1) US8324389B2 (en)
EP (1) EP2132198A1 (en)
JP (1) JP2010520215A (en)
KR (1) KR20090117833A (en)
CN (1) CN101679372A (en)
AR (1) AR065565A1 (en)
AU (1) AU2008251764B2 (en)
BR (1) BRPI0808526A2 (en)
CA (1) CA2678335A1 (en)
CL (1) CL2008000616A1 (en)
CO (1) CO6230987A2 (en)
EC (1) ECSP099673A (en)
GT (1) GT200900237A (en)
IL (1) IL200441A0 (en)
MA (1) MA31259B1 (en)
MX (1) MX2009009344A (en)
MY (1) MY148438A (en)
NZ (1) NZ579084A (en)
PE (1) PE20081801A1 (en)
RU (1) RU2483064C2 (en)
SG (1) SG179423A1 (en)
TN (1) TN2009000356A1 (en)
TW (1) TW200846341A (en)
WO (1) WO2008140850A1 (en)
ZA (1) ZA200905618B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2009147291A (en) * 2007-05-23 2011-06-27 Новартис АГ (CH) APPLICATION OF RAF INHIBITORS FOR TREATMENT OF THYROID CANCER
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
US10098859B2 (en) 2012-09-05 2018-10-16 Amri Ssci, Llc Cocrystals of p-coumaric acid
KR20180018800A (en) * 2015-06-19 2018-02-21 신-낫 프로덕츠 엔터프라이즈 엘엘씨 Pharmaceutical compositions of the carboplatin based co-crystals and uses thereof
JP7341060B2 (en) 2017-02-10 2023-09-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Methods and pharmaceutical compositions for the treatment of cancer associated with MAPK pathway activation
JP7416716B2 (en) 2017-12-28 2024-01-17 トラクト ファーマシューティカルズ インコーポレイテッド Stem cell culture system for columnar epithelial stem cells and related uses
RU2693004C1 (en) * 2019-03-15 2019-07-01 Лейсан Фаридовна Минигулова Anticancer tumor cisplatin composition with 6-phosphogluconate dehydrogenase inhibitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
US7071216B2 (en) * 2002-03-29 2006-07-04 Chiron Corporation Substituted benz-azoles and methods of their use as inhibitors of Raf kinase
TWI387592B (en) * 2005-08-30 2013-03-01 Novartis Ag Substituted benzimidazoles and methods of their use as inhibitors of kinases associated with tumorigenesis
AU2007275634B2 (en) * 2006-07-21 2011-01-20 Novartis Ag Formulations for benzimidazolyl pyridyl ethers
PE20130814A1 (en) * 2006-08-30 2013-08-08 Novartis Ag BENZIMIDAZOLYL PYRIDYL ETHER SALTS AND FORMULATIONS CONTAINING THEM

Also Published As

Publication number Publication date
MY148438A (en) 2013-04-30
NZ579084A (en) 2012-04-27
AR065565A1 (en) 2009-06-17
ZA200905618B (en) 2010-05-26
TW200846341A (en) 2008-12-01
SG179423A1 (en) 2012-04-27
CO6230987A2 (en) 2010-12-20
CA2678335A1 (en) 2008-11-20
MX2009009344A (en) 2009-09-11
AU2008251764B2 (en) 2012-09-13
KR20090117833A (en) 2009-11-12
BRPI0808526A2 (en) 2014-08-19
CL2008000616A1 (en) 2008-09-12
AU2008251764A1 (en) 2008-11-20
ECSP099673A (en) 2009-11-30
GT200900237A (en) 2010-06-24
US20100209418A1 (en) 2010-08-19
JP2010520215A (en) 2010-06-10
IL200441A0 (en) 2010-04-29
RU2009136308A (en) 2011-04-10
US8324389B2 (en) 2012-12-04
EP2132198A1 (en) 2009-12-16
WO2008140850A1 (en) 2008-11-20
MA31259B1 (en) 2010-03-01
RU2483064C2 (en) 2013-05-27
TN2009000356A1 (en) 2010-12-31
CN101679372A (en) 2010-03-24

Similar Documents

Publication Publication Date Title
PE20081801A1 (en) SOLID FORMS OF A RAF KINASE INHIBITOR
GT201400183A (en) 3 CRYSTALLINE PHOSPHINOSITIDE KINASE INHIBITORS
PE20142355A1 (en) 1-PIRAZOLIL-3- (4 - ((2-ANILINOPYRIMIDIN-4-IL) OXI) NAPHTHALEN-1-IL) UREAS AS INHIBITORS OF MITOGEN P38-ACTIVATED PROTEIN KINES
PE20140252A1 (en) ((R) - (E) -2- (4- (2- (5- (1- (3,5-DICHLOROPIDIN-4-IL) ETOXY) -1H-INDAZOL-3-IL) VINYL) -1H- PYRAZOLE-1-IL) CRYSTALLINE ETHANOL AS FGRF INHIBITOR
CL2015000578A1 (en) Compound n- (2- (6-fluoro-1-h-indol-3-yl) ethyl) -3- (2,2,3,3-tetrafluoropropoxy) benzylamine or its salt, 5-ht6 receptor antagonist; pharmaceutical composition; Use in the treatment of Alzheimer's disease.
CL2014000492A1 (en) Compounds derived from n- [3- (1,2,4-oxadiazol- (5-yl / amino / carbamoyl) phenyl] imidazo [1,2-a] pirdine-3-carboxamide, c-kit kinase inhibitors; pharmaceutical composition; and its use for the treatment of Alzheimer's disease, arthritis, atherosclerosis, among others
PE20141824A1 (en) THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
PE20140698A1 (en) CRYSTALLINE FORMS OF 5-CHLORO-N2- (2-ISOPROPOXY-5-METHYL-4-PIPERIDIN-4-IL-PHENYL) -N4- [2- (PROPAN-2-SULFONYL) -PHENYL] -PYRIMIDIN-2, 4 -DIAMINE
PE20171344A1 (en) CRYSTALLINE FORMS OF 5-CHLORO-N4- [2- (DIMETHYLPHOSPHORIL) PHENYL] -N2- {2-METOXY-4- [4- (4-METHYLPIPERAZIN-1-IL) PIPERIDIN-1-IL] PYRIMIDINE-2,4 -DIAMINE
BR112013032122A2 (en) modified release of 4-methyl-3 - [[4- (3-pyridinyl) -2-pyrimidinyl] amino] -n- [5- (4-methyl-1h-imidazol-1-yl) -3- (trifluoromethyl) phenyl] benzamide solubilized using organic acids
CL2008001076A1 (en) COMPOUNDS DERIVED FROM SULFONAMIDE; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF CANCER.
ECSP099755A (en) DERIVATIVES OF PIRROLOPIRIDINE AND ITS USE AS BACE INHIBITORS
PE20141421A1 (en) SUBSTITUTE 4-PHENYL-PYRIDINES FOR THE TREATMENT OF NK1 RECEPTOR-RELATED DISEASES
GEP201706735B (en) Kinase inhibitors
CL2011002925A1 (en) Isoquinolin-1 (2h) -one derived compounds, selective inhibitors of poly (adp-ribose) polymerase parp-1 activity; process to prepare them; pharmaceutical composition; and its use to treat a disease mediated by the protein parp-1.
PE20141148A1 (en) N- [5- (AMINOSULFONYL) -4 METHYL-1-3-THIAZOL-2-IL] -N-METHYL-2- [4- (2-PYRIDINYL) PHENYL] ACETAMIDE MONOHYDRATE MESILATE
CL2008000875A1 (en) COMPOUNDS DERIVED FROM IMIDAZOLIDIN-2-ONA; OBTAINING PROCESS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT AND / OR PROFILAXIS OF DISEASES SUCH AS DYSLIPIDEMIA, DIABETES, INFLAMMATORY DISEASES, AMONG OTHERS.
HK1215579A1 (en) Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof
CL2008001658A1 (en) Pharmaceutical composition comprising amorphous imatinib mesylate and a formulation principle that stabilizes the amorphous form; and its use to treat advanced and recently diagnosed chronic myeloid leukemia, chronic myelomonocytic leukemia, glioblastoma multiforme, among others.
MX2010008583A (en) Novel crystalline forms of 4- [4- (2-adamantylcarbam0yl) -5-tert-butyl-pyrazol-1-yl] benzoic acid.
CL2014000849A1 (en) Compounds derived from substituted benzylindazoles, bub1 kinase inhibitors; manufacturing procedure; pharmaceutical composition; pharmaceutical combination; and its use in the treatment of hyperproliferative diseases.
AR080490A1 (en) CRYSTAL FORMS OF AN INHIBITOR OF ELASTASA NEUTROFILA, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF THE DEFICIENCY OF ALFA-1-ANTITRIPSIN
CL2013000756A1 (en) Crystal form of the citrate diacid of (4s) -4- (5-phenyl-1,3,4-thiadiazol-2-yloxy) -1-azatricyclo [3.3.1.13.7] dean; Preparation process; pharmaceutical composition; and its use to treat or prevent a memory disorder, a cognitive disorder, neurodegeneration, among others.
AR068845A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING N- (3-METOXI-5-METHYLPIRAZIN-2-IL) -2- (4 - ((1,3,4-OXADIAZOL-2-IL)) PHENYL) PIRIDIN-3-SULFONAMIDE USEFUL CANCER TREATMENT
PE20141337A1 (en) IMMEDIATE RELEASE FORMULATION OF 4-METHYL-3 - [[4- (3-PYRIDINYL) -2-PYRIMIDINYL] -AMINO] -N- [5- (4-METHYL-1H-IMIDAZOL-1-IL) -3- (TRIFLUORO-METHYL) -PHENYL] -BENZAMIDE

Legal Events

Date Code Title Description
FC Refusal